These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38348768)

  • 1. Decoding the synergistic potential of MAZ-51 and zingerone as therapy for melanoma treatment in alignment with sustainable development goals.
    Letsoalo K; Nortje E; Patrick S; Nyakudya T; Hlophe Y
    Cell Biochem Funct; 2024 Mar; 42(2):e3950. PubMed ID: 38348768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor-C in activating vascular endothelial growth factor receptor-3 and chemokine receptor-4 in melanoma adhesion.
    Hlophe YN; Joubert AM
    J Cell Mol Med; 2022 Dec; 26(23):5743-5754. PubMed ID: 36398426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined treatment with zingerone and its novel derivative synergistically inhibits TGF-β1 induced epithelial-mesenchymal transition, migration and invasion of human hepatocellular carcinoma cells.
    Kim YJ; Jeon Y; Kim T; Lim WC; Ham J; Park YN; Kim TJ; Ko H
    Bioorg Med Chem Lett; 2017 Feb; 27(4):1081-1088. PubMed ID: 28110870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical markers and driving mechanisms in melanoma progression: VEGF-C, RhoC, c-Ski/SnoN and EGFR.
    Boone B; Brochez L
    Verh K Acad Geneeskd Belg; 2009; 71(5):251-94. PubMed ID: 20232784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
    Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
    Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of vascular endothelial growth factors and their receptors in malignant melanomas.
    Brychtova S; Bezdekova M; Brychta T; Tichy M
    Neoplasma; 2008; 55(4):273-9. PubMed ID: 18505336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
    Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
    Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study.
    Massi D; Puig S; Franchi A; Malvehy J; Vidal-Sicart S; González-Cao M; Baroni G; Ketabchi S; Palou J; Santucci M
    J Clin Pathol; 2006 Feb; 59(2):166-73. PubMed ID: 16443733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice.
    Stamatopoulos A; Stamatopoulos T; Gamie Z; Kenanidis E; Ribeiro RDC; Rankin KS; Gerrand C; Dalgarno K; Tsiridis E
    J Bone Oncol; 2019 Jun; 16():100231. PubMed ID: 30956944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
    Del Vecchio M; Mortarini R; Canova S; Di Guardo L; Pimpinelli N; Sertoli MR; Bedognetti D; Queirolo P; Morosini P; Perrone T; Bajetta E; Anichini A
    Clin Cancer Res; 2010 Dec; 16(23):5862-72. PubMed ID: 21030496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zingerone suppresses cell proliferation via inducing cellular apoptosis and inhibition of the PI3K/AKT/mTOR signaling pathway in human prostate cancer PC-3 cells.
    Qian S; Fang H; Zheng L; Liu M
    J Biochem Mol Toxicol; 2021 Jan; 35(1):e22611. PubMed ID: 32905641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
    Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis.
    Zhuo W; Jia L; Song N; Lu XA; Ding Y; Wang X; Song X; Fu Y; Luo Y
    Clin Cancer Res; 2012 Oct; 18(19):5387-98. PubMed ID: 22932666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of Vascular Endothelial Growth Factor (VEGF)-C and VEGF-D in the Progression of Cutaneous Melanoma.
    Špirić Z; Eri Ž; Erić M
    Int J Surg Pathol; 2015 Dec; 23(8):629-37. PubMed ID: 25911567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locally generated VGVAPG and VAPG elastin-derived peptides amplify melanoma invasion via the galectin-3 receptor.
    Pocza P; Süli-Vargha H; Darvas Z; Falus A
    Int J Cancer; 2008 May; 122(9):1972-80. PubMed ID: 18076073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLT-VEGF reduces lung metastases, decreases tumor recurrence, and improves survival in an orthotopic melanoma model.
    Ackerman R; Backer JM; Backer M; Skariah S; Hamby CV
    Toxins (Basel); 2010 Sep; 2(9):2242-57. PubMed ID: 22069683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
    Atzori MG; Ceci C; Ruffini F; Trapani M; Barbaccia ML; Tentori L; D'Atri S; Lacal PM; Graziani G
    J Cell Mol Med; 2020 Jan; 24(1):465-475. PubMed ID: 31758648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the VEGF-C/VEGFR-3 axis in cancer progression.
    Su JL; Yen CJ; Chen PS; Chuang SE; Hong CC; Kuo IH; Chen HY; Hung MC; Kuo ML
    Br J Cancer; 2007 Feb; 96(4):541-5. PubMed ID: 17164762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1/PD-L1 and VEGF-A/VEGF-C expression in lymph node microenvironment and association with melanoma metastasis and survival.
    Alessi C; Scapulatempo Neto C; Viana CR; Vazquez VL
    Melanoma Res; 2017 Dec; 27(6):565-572. PubMed ID: 28984690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.